Meta-Analysis of Aidi Injection and First-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapy in Treating Advanced Non-Small Cell Lung Cancer.
- 2021-01-01
- Journal of evidence-based integrative medicine 26
- Na Xiao
- Hailang He
- Jing Wang
- Li Zhang
- Brandon Chow
- Fanchao Feng
- Yong Xu
- Jingyi Huang
- Xianmei Zhou
- Rui Dong
- PubMed: 33926244
- DOI: 10.1177/2515690x211010733
Study Design
- Type
- Meta-Analysis
- Sample size
- n = 667
- Population
- 667 patients diagnosed with stage III-IV NSCLC
- Methods
- Systematic review and meta-analysis of 8 RCTs comparing Aidi injection combined with EGFR-TKI vs EGFR-TKI alone; searches up to June 2020
- Funding
- Unclear
The combination of Aidi injection (ADI) and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) in treating non-small cell lung cancer (NSCLC) has been reported, but the effects of this therapy have not been systematically assessed. Randomized controlled trials (RCTs) published before June 2020 were searched from 6 databases. Two reviewers independently assessed the methodological quality of 8 RCTs involving 667 patients diagnosed with stage III-IV NSCLC. We found that ADI combined with EGFR-TKI increased the objective response rate (ORR) significantly (relative risk 95% confidence interval P < 0.0001). There was also improvement in the disease control rate (DCR) (RR: 1.25; 95% CI: 1.11-1.40, P = 0.0002) as compared with EGFR-TKI alone. This therapy also increased the percentage of CD3+ cells (weighted mean difference 95% CI: 4.62-15.10), CD4+ cells (WMD: 6.10; 95% CI: 1.67-10.53), and the CD4+/CD8+ (WMD: 0.35; 95% CI: 0.28-0.43). With regard to drug toxicity, the occurrence of rash was significantly reduced by ADI combined with EGFR-TKI (RR: 0.78, 95% CI: 0.63-0.97, P = 0.03); however, we did not find a significant reduction in the occurrence of dry skin, nausea and vomiting, as well as diarrhea between the 2 therapies. ADI combined with first-generation EGFR-TKIs may be more effective in improving tumor response, reducing the occurrence of rash, and enhancing immune function in NSCLC than EGFR-TKI alone.